PD 145246
Latest Information Update: 30 Jan 2007
Price :
$50 *
At a glance
- Originator Pfizer
- Class Nonsteroidal anti-inflammatories; Pyrimidines; Small molecules
- Mechanism of Action 5-lipoxygenase inhibitors; Cyclooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 09 Mar 1999 No-Development-Reported for Inflammation in USA (Unknown route)
- 11 Nov 1996 Preclinical development for Inflammation in USA (Unknown route)